{"entity":{"id":"9mw2921","kind":"drug","name":"9MW2921","aka":[],"tldr":"9MW2921 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.","summary":"ASCO 2025 abstract 3029 reports 39 treated patients at the November 12, 2024 cutoff. Across doses, 12/38 efficacy-evaluable patients had partial responses. At 3.0 mg/kg, responses were 8/19 (42.1%); this is a dose subgroup, not the full treated population. All three patients at 4.5 mg/kg experienced dose-limiting toxicity and that dose was considered intolerable. The nonrandomized solid-tumor study does not establish TNBC-specific benefit.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1200/jco.2025.43.16_suppl.3029"},{"label":"ClinicalTrials.gov NCT05990452","url":"https://clinicaltrials.gov/study/NCT05990452"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05990452"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"Mtoxin (camptothecin-based payload), DAR 4","mechanism":"TROP2-directed ADC carrying a camptothecin-based Mtoxin payload with site-specific conjugation.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/9mw2921/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct05990452","kind":"trial","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","route":"/trials/nct05990452/"}]}}